As of 2024-10-14, the EV/EBITDA ratio of Inovio Pharmaceuticals Inc (INO) is -0.99. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. INO's latest enterprise value is 114.88 mil USD. INO's TTM EBITDA according to its financial statements is -116.52 mil USD. Dividing these 2 quantities gives us the above INO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.9x - 18.6x | 16.2x |
| Forward P/E multiples | 18.0x - 21.3x | 19.6x |
| Fair Price | (79.47) - (82.16) | (79.24) |
| Upside | -1482.0% - -1528.9% | -1478.1% |
| Date | EV/EBITDA |
| 2024-10-11 | -0.99 |
| 2024-10-10 | -0.91 |
| 2024-10-09 | -0.93 |
| 2024-10-08 | -0.97 |
| 2024-10-07 | -0.89 |
| 2024-10-04 | -0.94 |
| 2024-10-03 | -0.96 |
| 2024-10-02 | -0.97 |
| 2024-10-01 | -0.96 |
| 2024-09-30 | -0.99 |
| 2024-09-27 | -1.01 |
| 2024-09-26 | -0.93 |
| 2024-09-25 | -0.93 |
| 2024-09-24 | -1.03 |
| 2024-09-23 | -1.01 |
| 2024-09-20 | -1.15 |
| 2024-09-19 | -1.20 |
| 2024-09-18 | -1.21 |
| 2024-09-17 | -1.22 |
| 2024-09-16 | -1.22 |
| 2024-09-13 | -1.22 |
| 2024-09-12 | -1.18 |
| 2024-09-11 | -1.16 |
| 2024-09-10 | -1.14 |
| 2024-09-09 | -1.13 |
| 2024-09-06 | -1.10 |
| 2024-09-05 | -1.15 |
| 2024-09-04 | -1.17 |
| 2024-09-03 | -1.14 |
| 2024-08-30 | -1.31 |
| 2024-08-29 | -1.34 |
| 2024-08-28 | -1.29 |
| 2024-08-27 | -1.36 |
| 2024-08-26 | -1.38 |
| 2024-08-23 | -1.38 |
| 2024-08-22 | -1.35 |
| 2024-08-21 | -1.40 |
| 2024-08-20 | -1.35 |
| 2024-08-19 | -1.46 |
| 2024-08-16 | -1.45 |
| 2024-08-15 | -1.44 |
| 2024-08-14 | -1.45 |
| 2024-08-13 | -1.46 |
| 2024-08-12 | -1.56 |
| 2024-08-09 | -1.59 |
| 2024-08-08 | -1.65 |
| 2024-08-07 | -1.62 |
| 2024-08-06 | -1.64 |
| 2024-08-05 | -1.70 |
| 2024-08-02 | -1.82 |